The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Halozyme (NASDAQ:HALO) stock surged after 2025 guidance upgrade and a Morgan Stanley rating boost. Read more here.

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

Halozyme Therapeutics Inc (HALO) reports a 41% revenue increase, raises 2025 guidance, and advances share repurchase program ...

Detailed price information for Halozyme Therapeutic (HALO-Q) from The Globe and Mail including charting and trades.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?